Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2024

Open Access 01-12-2024 | Stroke | Research

Geographic differences in pharmacotherapy patterns and outcomes of acute ischemic stroke in China

Authors: Ying Li, Qianhua Ou, Yuxuan Lu, Zhiyuan Shen, Jieyu Li, Zhuangzhuang Zhang, Liwen Tai, Guozhong Li, Huisheng Chen, Guiru Zhang, Lei Zhang, Xuwen Sun, Jinhua Qiu, Yan Wei, Sainan Zhu, Zhaoxia Wang, Weiping Sun, Yining Huang

Published in: BMC Neurology | Issue 1/2024

Login to get access

Abstract

Background

Vast economic and healthcare status discrepancies exist among regions in China, contributing to different treatment patterns. This study was aimed to investigate the current status of pharmacotherapy for acute ischemic stroke (AIS) and outcomes in China and explore the geographic variation in stroke care.

Methods

This study was a multicenter prospective registry study, which collected the data of patients with AIS from 80 hospitals in 46 cities in 2015–2017 across China. Poor functional outcome defined as a modified Rankin Scale score of 3–6 was assessed at 3 and 12 months. Multivariate logistic regression was used.

Results

Among 9973 eligible patients, the number of receiving intravenous thrombolysis (IVT), antiplatelet agents, anticoagulants, statin and human urinary kallidinogenase was 429 (4.3%), 9363 (93.9%), 1063 (10.7%), 6828 (74.7%) and 5112 (51.2%), respectively. Multivariable analysis showed IVT use in northeastern was significantly more frequent than in eastern region (OR = 3.17, 95% CI, 2.53–3.99), while the antiplatelets agents use were less frequent (OR = 0.46, 95%CI: 0.38–0.57). The proportions of poor outcomes at 3 and 12 months were 20.7% and 15.8%, respectively. Multivariate analysis showed AIS patients from northeastern and central region had significantly lower risk of poor outcome at month 3 and 12 than those from eastern region (all P < 0.05).

Conclusions

There was a low IVT use and a high antiplatelet agent and statin use for AIS in China. The pharmacotherapy and prognosis of AIS had variation by geographic region.

Trial registration

This study was registered with ClinicalTrials.gov (NCT02470624).
Literature
1.
Global regional. National burden of neurological disorders during 1990–2015: a systematic analysis for the global burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877–97.CrossRef
2.
3.
Wang YJ, Li ZX, Gu HQ, Zhai Y, Jiang Y, Zhao XQ, Wang YL, Yang X, Wang CJ, Meng X, et al. China Stroke statistics 2019: a Report from the National Center for Healthcare Quality Management in Neurological diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke collaborations. Stroke Vasc Neurol. 2020;5(3):211–39.PubMedPubMedCentralCrossRef
4.
Wangqin R, Laskowitz DT, Wang Y, Li Z, Wang Y, Liu L, Liang L, Matsouaka RA, Saver JL, Fonarow GC, et al. International Comparison of Patient Characteristics and Quality of Care for ischemic stroke: analysis of the China National Stroke Registry and the American Heart Association get with the guidelines–Stroke Program. J Am Heart Assoc. 2018;7(20):e010623.PubMedPubMedCentralCrossRef
5.
Ye Q, Zhai F, Chao B, Cao L, Xu Y, Zhang P, Han H, Wang L, Xu B, Chen W, et al. Rates of intravenous thrombolysis and endovascular therapy for acute ischaemic stroke in China between 2019 and 2020. Lancet Reg Health West Pac. 2022;21:100406.PubMedPubMedCentralCrossRef
6.
Wu S, Wu B, Liu M, Chen Z, Wang W, Anderson CS, Sandercock P, Wang Y, Huang Y, Cui L, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019;18(4):394–405.PubMedCrossRef
7.
Wang Y, Liao X, Zhao X, Wang DZ, Wang C, Nguyen-Huynh MN, Zhou Y, Liu L, Wang X, Liu G, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke. 2011;42(6):1658–64.PubMedCrossRef
8.
Li Z, Wang C, Zhao X, Liu L, Wang C, Li H, Shen H, Liang L, Bettger J, Yang Q, et al. Substantial progress yet significant opportunity for improvement in Stroke Care in China. Stroke. 2016;47(11):2843–9.PubMedCrossRef
9.
Lewis WR, Fonarow GC, Grau-Sepulveda MV, Smith EE, Bhatt DL, Hernandez AF, Olson D, Peterson ED, Schwamm LH. Improvement in use of anticoagulation therapy in patients with ischemic stroke: results from get with the guidelines-Stroke. Am Heart J. 2011;162(4):692–699e692.PubMedCrossRef
10.
Chinese Stroke Society of the Chinese Society of Neurology. 2014 Chinese guidelines for diagnosis and treatment of Acute Ischaemic Stroke. Chin J Neurol. 2015;48:246–57.
11.
Liu J, Zhang Y. Health status and health disparity in China: a demographic and socioeconomic perspective. Chin Popul Dev Stud. 2019;2:301–22.CrossRef
12.
Chen T, Wang Y, Luo X, Rao Y, Hua L. Inter-provincial inequality of public health services in China: the perspective of local officials’ behavior. Int J Equity Health. 2018;17(1):108.PubMedCentralCrossRef
13.
Sun W, Ou Q, Zhang Z, Qu J, Huang Y. Chinese acute ischemic stroke treatment outcome registry (CASTOR): protocol for a prospective registry study on patterns of real-world treatment of acute ischemic stroke in China. BMC Complement Altern Med. 2017;17(1):357.PubMedPubMedCentralCrossRef
14.
15.
16.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41.PubMedCrossRef
17.
Jin H, Zhu S, Wei JW, Wang J, Liu M, Wu Y, Wong LK, Cheng Y, Xu E, Yang Q, et al. Factors associated with prehospital delays in the presentation of acute stroke in urban China. Stroke. 2012;43(2):362–70.PubMedCrossRef
18.
19.
National Institute of Neurological. Stroke rt PASSG: tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7.CrossRef
20.
Jauch EC, Saver JL, Adams HP Jr., Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr., Qureshi AI, Rosenfield K, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.PubMedCrossRef
21.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al. 2018 guidelines for the early management of patients with Acute ischemic stroke: a Guideline for Healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–e110.
22.
European Stroke Organisation, Executive C, Committee ESOW. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457–507.CrossRef
23.
Chen Y, Li J, Dang C, Tan S, Ouyang F, Li J, Yu J, Zeng J, Fan Y. Impact of stroke center certification on rt-PA thrombolysis after acute ischemic stroke in South China from 2015 to 2020. Int J Stroke. 2022;17(5):559–65.PubMedCrossRef
24.
Suolang D, Chen BJ, Wang NY, Gottesman RF, Faigle R. Temporal trends in Stroke Thrombolysis in the US by Race and Ethnicity, 2009–2018. JAMA. 2021;326(17):1741–3.PubMedPubMedCentralCrossRef
25.
Chen H, Shi L, Wang N, Han Y, Lin Y, Dai M, Liu H, Dong X, Xue M, Xu H. Analysis on geographic variations in hospital deaths and endovascular therapy in ischaemic stroke patients: an observational cross-sectional study in China. BMJ Open. 2019;9(6):e029079.PubMedPubMedCentralCrossRef
26.
Chen Q. Intravenous thrombolysis with urokinase for acute cerebral infarctions. Chin J Neurol. 2002;35:210–3.ADS
27.
The International Stroke Trial (IST). A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349(9065):1569–81.CrossRef
28.
CAST. Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349(9066):1641–9.CrossRef
29.
Wei JW, Wang JG, Huang Y, Liu M, Wu Y, Wong LK, Cheng Y, Xu E, Yang Q, Arima H, et al. Secondary prevention of ischemic stroke in urban China. Stroke. 2010;41(5):967–74.PubMedCrossRef
30.
Allen NB, Kaltenbach L, Goldstein LB, Olson DM, Smith EE, Peterson ED, Schwamm L, Lichtman JH. Regional variation in recommended treatments for ischemic stroke and TIA: get with the guidelines–stroke 2003–2010. Stroke. 2012;43(7):1858–64.PubMedCrossRef
31.
Al-Khaled M, Matthis C, Eggers J. Statin treatment in patients with acute ischemic stroke. Int J Stroke. 2014;9(5):597–601.PubMedCrossRef
32.
33.
Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.PubMedCrossRef
34.
Whiteley WN, Adams HP Jr., Bath PM, Berge E, Sandset PM, Dennis M, Murray GD, Wong KS, Sandercock PA. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol. 2013;12(6):539–45.PubMedPubMedCentralCrossRef
35.
Wang X, Ouyang M, Yang J, Song L, Yang M, Anderson CS. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev. 2021;10(10):CD000024.PubMed
36.
group ISTc, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352–63.CrossRef
37.
Al-Sadat A, Sunbulli M, Chaturvedi S. Use of intravenous heparin by north American neurologists: do the data matter? Stroke. 2002;33(6):1574–7.
38.
Duffy BK, Phillips PA, Davis SM, Donnan GA, Vedadhaghi ME. Stroke in hospitals: an Australian review of treatment i: evidence-based care and outcomes of acute stroke managed in hospital specialty units. Med J Aust. 2003;178(7):318–23.PubMedCrossRef
39.
Huang Y, Wang JG, Wei JW, Headley AP, Wong LK, Heeley EL, Arima H, Sun J, Li Q, Liu M, et al. Age and gender variations in the management of ischaemic stroke in China. Int J Stroke. 2010;5(5):351–9.PubMedCrossRef
40.
He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, Tong W, Liu C, Xu T, Ju Z, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014;311(5):479–89.PubMedCrossRef
41.
Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, et al. Regional differences in Antithrombotic Treatment for Atrial Fibrillation: insights from the GLORIA-AF Phase II Registry. Thromb Haemost. 2017;117(12):2376–88.PubMedPubMedCentralCrossRef
42.
Nagano H, Suzuki T, Tomoguri T, Hayashi M, Tsurumi K. Pharmacological studies on human urinary kallidinogenase (SK-827): effects on cerebral metabolism. Yakugaku Zasshi. 1993;113(11):825–8.PubMedCrossRef
43.
Han L, Li J, Chen Y, Zhang M, Qian L, Chen Y, Wu Z, Xu Y, Li J. Human urinary kallidinogenase promotes angiogenesis and cerebral perfusion in experimental stroke. PLoS ONE. 2015;10(7):e0134543.PubMedPubMedCentralCrossRef
44.
Ding DY, Lyu CZ, Ding MP, Su BH, Chen F. A multicenter, randomized, double—blinded and placebo—controlled study of acute brain infarction treated by human urinary kallidinogenase. Chin J Neurol. 2007;40(5):307–10.
45.
Luengo-Fernandez R, Paul NL, Gray AM, Pendlebury ST, Bull LM, Welch SJ, Cuthbertson FC, Rothwell PM, Oxford Vascular S. Population-based study of disability and institutionalization after transient ischemic attack and stroke: 10-year results of the Oxford Vascular Study. Stroke. 2013;44(10):2854–61.PubMedPubMedCentralCrossRef
46.
Ouyang M, Zhang Y, Wang X, Song L, Billot L, Robinson T, Lavados PM, Arima H, Hackett ML. Olavarría VVet al. Quantifying regional variations in components of acute stroke unit (ASU) care in the international HeadPoST study. J Neurol Sci. 2020;419:117187.PubMedCrossRef
47.
Gezmu T, Gizzi MS, Kirmani JF, Schneider D, Moussavi M. Disparities in acute stroke severity, outcomes, and care relative to health insurance status. J Stroke Cerebrovasc Dis. 2014;23(2):e93–8.PubMedCrossRef
48.
Oostema JA, Nasiri M, Chassee T, Reeves MJ. The quality of prehospital ischemic stroke care: compliance with guidelines and impact on in-hospital stroke response. J Stroke Cerebrovasc Dis. 2014;23(10):2773–9.PubMedCrossRef
Metadata
Title
Geographic differences in pharmacotherapy patterns and outcomes of acute ischemic stroke in China
Authors
Ying Li
Qianhua Ou
Yuxuan Lu
Zhiyuan Shen
Jieyu Li
Zhuangzhuang Zhang
Liwen Tai
Guozhong Li
Huisheng Chen
Guiru Zhang
Lei Zhang
Xuwen Sun
Jinhua Qiu
Yan Wei
Sainan Zhu
Zhaoxia Wang
Weiping Sun
Yining Huang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2024
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-024-03564-9

Other articles of this Issue 1/2024

BMC Neurology 1/2024 Go to the issue

Case Report

Reversible encephalitis-like episodes in fragile X-associated tremor/ataxia syndrome: a case report

Research

QTc prolongation after aneurysmal subarachnoid hemorrhage might be associated with worse neurologic outcome in patients receiving microsurgical clipping or embolization of the intracranial aneurysms: a retrospective observational study

Research

Symptoms at stroke onset as described by patients: a qualitative study

Research

Effectiveness of vestibular rehabilitation on postural balance in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials

Research

The associations between peripheral inflammatory and lipid parameters, white matter hyperintensity, and cognitive function in patients with non-disabling ischemic cerebrovascular events

Research

Pain assessment tools in adults with communication disorders: systematic review and meta-analysis